Cargando…
Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors
BACKGROUND: The prognosis of thymic epithelial tumors (TETs) currently relies on the commonly adopted WHO classification and Masaoka staging system, which cannot reflect the undefined biological behaviors limiting them as prognostic factors. METHODS: In this study, we first identified 40 genes and 1...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575130/ https://www.ncbi.nlm.nih.gov/pubmed/36073321 http://dx.doi.org/10.1111/1759-7714.14628 |
_version_ | 1784811256846221312 |
---|---|
author | Guan, Wei Li, Songlin Zhang, Zhimin Xiao, He He, Juan Li, Jian He, Xuan Luo, Jia Liu, Yun Lei, Lin Ma, Jungang Chen, Lizhao Chen, Chuan |
author_facet | Guan, Wei Li, Songlin Zhang, Zhimin Xiao, He He, Juan Li, Jian He, Xuan Luo, Jia Liu, Yun Lei, Lin Ma, Jungang Chen, Lizhao Chen, Chuan |
author_sort | Guan, Wei |
collection | PubMed |
description | BACKGROUND: The prognosis of thymic epithelial tumors (TETs) currently relies on the commonly adopted WHO classification and Masaoka staging system, which cannot reflect the undefined biological behaviors limiting them as prognostic factors. METHODS: In this study, we first identified 40 genes and 179 genes, respectively that were epigenetically upregulated and silenced, corresponding to a total of 509 functionally methylated CpG sites between thymomas and thymic carcinomas by using the TCGA dataset. RESULTS: The methylation β‐values of cg20068620 in MAPK4 and cg18770944 in USP51 were significantly associated with recurrence‐free survival (RFS). In the independent validation cohort, only WHO classification and methylation β‐values of cg20068620 in MAPK4 were independent prognostic factors for RFS in Chinese patients with TETs. A linear weighted model including these two factors was used to calculate the recurrence risk score (RRS). Time‐dependent ROC curve analysis revealed that RRS was overwhelmingly superior to WHO classification for predicting 3‐, 5‐, and 10‐year RFS and Masaoka stage for 3‐ and 5‐year RFS. CONCLUSIONS: These results suggested that the methylation site cg20068620 in MAPK4 can improve the accuracy of the WHO classification alone regarding the prognostic value of TETs recurrence. |
format | Online Article Text |
id | pubmed-9575130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-95751302022-10-17 Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors Guan, Wei Li, Songlin Zhang, Zhimin Xiao, He He, Juan Li, Jian He, Xuan Luo, Jia Liu, Yun Lei, Lin Ma, Jungang Chen, Lizhao Chen, Chuan Thorac Cancer Original Articles BACKGROUND: The prognosis of thymic epithelial tumors (TETs) currently relies on the commonly adopted WHO classification and Masaoka staging system, which cannot reflect the undefined biological behaviors limiting them as prognostic factors. METHODS: In this study, we first identified 40 genes and 179 genes, respectively that were epigenetically upregulated and silenced, corresponding to a total of 509 functionally methylated CpG sites between thymomas and thymic carcinomas by using the TCGA dataset. RESULTS: The methylation β‐values of cg20068620 in MAPK4 and cg18770944 in USP51 were significantly associated with recurrence‐free survival (RFS). In the independent validation cohort, only WHO classification and methylation β‐values of cg20068620 in MAPK4 were independent prognostic factors for RFS in Chinese patients with TETs. A linear weighted model including these two factors was used to calculate the recurrence risk score (RRS). Time‐dependent ROC curve analysis revealed that RRS was overwhelmingly superior to WHO classification for predicting 3‐, 5‐, and 10‐year RFS and Masaoka stage for 3‐ and 5‐year RFS. CONCLUSIONS: These results suggested that the methylation site cg20068620 in MAPK4 can improve the accuracy of the WHO classification alone regarding the prognostic value of TETs recurrence. John Wiley & Sons Australia, Ltd 2022-09-08 2022-10 /pmc/articles/PMC9575130/ /pubmed/36073321 http://dx.doi.org/10.1111/1759-7714.14628 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Guan, Wei Li, Songlin Zhang, Zhimin Xiao, He He, Juan Li, Jian He, Xuan Luo, Jia Liu, Yun Lei, Lin Ma, Jungang Chen, Lizhao Chen, Chuan Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors |
title | Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors |
title_full | Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors |
title_fullStr | Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors |
title_full_unstemmed | Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors |
title_short | Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors |
title_sort | promotor methylation status of mapk4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575130/ https://www.ncbi.nlm.nih.gov/pubmed/36073321 http://dx.doi.org/10.1111/1759-7714.14628 |
work_keys_str_mv | AT guanwei promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT lisonglin promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT zhangzhimin promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT xiaohe promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT hejuan promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT lijian promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT hexuan promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT luojia promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT liuyun promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT leilin promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT majungang promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT chenlizhao promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors AT chenchuan promotormethylationstatusofmapk4isanovelepigeneticbiomarkerforprognosisofrecurrenceinpatientswiththymicepithelialtumors |